Abstracts tagged "Adalimumab and biosimilars"

Abstract Number: 2446 • 2017 ACR/ARHP Annual Meeting
Minimal and Comparable Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Who Continued SB5 or Reference Adalimumab and Who Switched to SB5
Michael Weinblatt¹, Asta Baranauskaite², Jeehoon Ghil³, Soo Yeon Cheong³ and Evelyn Hong³, ¹Brigham and Women’s Hospital, Boston, MA, ²Lithuanian University of Health Sciences, Kaunas, Lithuania, ³Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose : SB5 is a biologic agent developed as a biosimilar of the reference adalimumab (ADL). One year results including radiographic progression from the phase…
Abstract Number: 2757 • 2015 ACR/ARHP Annual Meeting
Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Alan K. Matsumoto¹, Karel Pavelka², Warren Rizzo³, Ramesh Gupta⁴, William Shergy⁵, Pawel Heycaj⁶, Nan Zhang⁷ and Primal P. Kaur⁸, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²Charles University, Prague, Czech Republic, ³Advanced Arthritis Care & Research, Scottsdale, AZ, ⁴Private Practice, Rheumatology, Memphis, TN, ⁵RANA Clinical Research Center, Huntsville, AL, ⁶Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ⁷Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁸Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons…
Abstract Number: 1503 • 2014 ACR/ARHP Annual Meeting
Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501
Teresa Born¹, Jyoti Velayudhan², Yuh-fung Chen³, Heather Thomas⁴, Christina Pastula², Gwen Maher³ and Ryan Brown⁴, ¹Biosimilars Process Development, Amgen, Seattle, WA, ²Functional Biocharacterization, Amgen, Seattle, WA, ³Functional Biocharacterization, Amgen, Thousand Oaks, CA, ⁴Inflammation Research, Amgen, Seattle, WA
Background/Purpose: ABP 501 is being developed as a biosimilar to adalimumab, a recombinant monoclonal antibody that binds tumor necrosis factor alpha (TNF) thus inhibiting engagement…